Dechert LLP is advising the selling shareholders on the proposed sale of STAT-Dx, a privately owned Spanish molecular diagnostics company, to QIAGEN N.V, a leading provider of sample and assay technologies for molecular diagnostics listed on the New York Stock and Frankfurt Prime Standard exchanges, for approximately US$191 million (including milestones). The transaction is expected to close during the second quarter of 2018, subject to the successful completion of defined development activities by STAT-Dx.
Jordi Carrera, co-founder and CEO of STAT-Dx, said, “The team of Dechert understood the deal requirements from time zero, and provided options and solutions from both the legal and business standpoint. Always available, they are great professionals to work with.”
The team is being led by London-based corporate partner Graham Defries with support from partner Andrew Harrow, counsel Jonathan Schur, and associates Kenny MacLeod, Isabella Sharpley and Rose Limaye.
About Dechert
Dechert is a global law firm focused on sectors with the greatest complexities and highest regulatory demands. We deliver practical commercial insight and judgment to our clients' most important matters. Nothing stands in the way of giving clients the best of the firm's entrepreneurial energy and seamless collaboration in a way that is distinctively Dechert.
Subscribe to Dechert Updates